Exploring autoantibodies in systemic lupus erythematosus
Evaluation of Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in the Pathogenesis for Patients With Systemic Lupus Erythematosus (SLE)
This study is trying to see how certain autoantibodies affect the immune system in people with systemic lupus erythematosus to better understand the disease and improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 2 sites (Grenoble and 1 other locations) |
| Trial ID | NCT05193591 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the role of specific autoantibodies (anti-C1s, anti-HMGB1, and anti-C1q) in patients with systemic lupus erythematosus (SLE). The research focuses on understanding how these autoantibodies interact with key proteins involved in the immune response and their potential impact on disease pathology. By evaluating the effects of these autoantibodies on various molecular interactions, the study aims to shed light on their pathogenic roles and implications for SLE management.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a confirmed diagnosis of systemic lupus erythematosus and active lupus nephritis.
Not a fit: Patients who are minors, pregnant, breastfeeding, or undergoing dialysis or plasma exchange may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a better understanding of lupus pathology and inform new therapeutic strategies for patients with systemic lupus erythematosus.
How similar studies have performed: While the specific approach of evaluating these autoantibodies is novel, related studies have explored the role of autoantibodies in autoimmune diseases with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years old * Weight ≥ 40 Kg * Patients who have valid health insurance * Patients with lupus diagnosis criteria (EULAR-ACR-2019) * Active lupus nephritis defined by SLEDAI score \>5 and joint and/or kidney involvement. Exclusion Criteria: * Patient protected by law (minors, pregnant or breastfeeding women, subject under guardianship or curatorship, deprived of liberty or enforced hospitalized, under administrative or judicial supervision). * Patient on dialysis or on plasma exchange.
Where this trial is running
Grenoble and 1 other locations
- CHU Grenoble Alpes — Grenoble, France (Recruiting)
- AP-HM_Hôpital de la Conception — Marseille, France (Recruiting)
Study contacts
- Principal investigator: Chantal DUMESTRE-PERARD, Professor — Grenoble Alpes University Hospital
- Study coordinator: Chantal DUMESTRE-PERARD, Professor
- Email: cdumestre-perard@chu-grenoble.fr
- Phone: 0476765015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.